Krot Studio
Messenger RNA drug developers Arcturus Therapeutics (ARCT) and Moderna (MRNA) traded lower on Friday after BioNTech (BNTX) decided to halt a mid-stage trial for its mRNA-based cancer vaccine BNT122 developed with Roche (RHHBY) due to efficacy concerns.
Arcturus (ARCT
